| Literature DB >> 26092582 |
Graeme B Mulholland1, Caroline C Jeffery2, Paras Satija3, David W J Côté4.
Abstract
BACKGROUND: Immunoglobulin G4 related disease (IgG4-RD) is a poorly understood chronic inflammatory disorder affecting the middle-aged and elderly that can present to the otolaryngologist. We aim to summarize the current literature regarding the manifestations and management of IgG4-RD in the head and neck.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26092582 PMCID: PMC4482182 DOI: 10.1186/s40463-015-0071-9
Source DB: PubMed Journal: J Otolaryngol Head Neck Surg ISSN: 1916-0208
Fig. 1Flow chart of studies obtained through literature search, eligible and excluded (Uploaded separately as per submission instructions)
Country of origin and characteristics of included articles
| N (Articles) | % | N (Individual Cases) | % | |||
|---|---|---|---|---|---|---|
| Total number of studies | 43 | 484 | ||||
| Case Reports | 21 | 48.8 | 21 | 4.3 | ||
| Small Case Series | 17 | 39.5 | 107 | 22.1 | ||
| Large Case Series | 5 | 11.6 | 356 | 73.6 | ||
| Country of Origin | North America | 10 | 23.3 | 27 | 5.6 | |
| Canada | 1 | 2.3 | 1 | 0.2 | ||
| USA | 9 | 20.9 | 26 | 5.4 | ||
| Asia | 22 | 51.2 | 429 | 88.6 | ||
| Japan | 18 | 41.9 | 419 | 86.6 | ||
| Hong Kong | 2 | 4.7 | 8 | 1.7 | ||
| Taiwan | 1 | 2.3 | 1 | 0.2 | ||
| Singapore | 1 | 2.3 | 1 | 0.2 | ||
| Oceania | 6 | 14.0 | 7 | 1.4 | ||
| Australia | 5 | 11.6 | 6 | 1.2 | ||
| New Zealand | 1 | 2.3 | 1 | 0.2 | ||
| Europe | 4 | 9.3 | 20 | 4.1 | ||
| United Kingdom | 1 | 2.3 | 1 | 0.2 | ||
| Netherlands | 1 | 2.3 | 12 | 2.5 | ||
| Czech Republic | 1 | 2.3 | 6 | 1.2 | ||
| Switzerland | 1 | 2.3 | 1 | 0.2 | ||
| South America | 1 | 2.3 | 1 | 0.2 | ||
| Brazil | 1 | 2.3 | 1 | 0.2 |
Basic patient demographics
| Total number of Patients | 484 |
| Average Age (years) | 60.4 |
| Percent Males | 47.5 % |
Systemic and head and neck manifestations
| Head & Neck Manifestations | Site | Subsite | n | % |
|---|---|---|---|---|
| Total presentations | 730 | |||
| Orbit | 384 | 52.6 | ||
| Lacrimal Gland | 136 | 18.6 | ||
| Extra Ocular Muscles | 9 | 1.2 | ||
| Optic Nerve | 5 | 0.7 | ||
| Salivary Glands | 162 | 22.2 | ||
| Submandibular Gland | 107 | 14.7 | ||
| Parotid Gland | 29 | 4.0 | ||
| Sublingual Gland | 1 | 0.1 | ||
| Minor Salivary Gland | 1 | 0.1 | ||
| Thyroid | 31 | 4.2 | ||
| Facial Skin | 6 | 0.8 | ||
| Trigeminal Nerve | 1 | 0.1 | ||
| Cervical Lymphadenopathy | 22 | 3.0 | ||
| Non Head & Neck Manifestations | Site | n | % | |
| Other Organ Involvement | 68 | 9.3 | ||
| Mediastinal/Pelvic Lymphadenopathy | 56 | 7.7 |
Laboratory and histologic findings
| Mean Values | |
|---|---|
| Serum IgG4 (mg/dL) | 702.9 |
| Serum IgG (mg/dL) | 2445.0 |
| IgG4 + ve Plasma Cells / HPF | 69.8 |
| IgG4 + ve Cells / IgG Containing Cells | 48.0 % |
Treatment and progress
| Treatments Received by Patients ( | n | % | |
|---|---|---|---|
| Surgical Management Alone | 15 | 11.6 | |
| Combined Surgical and Medical Management | 4 | 3.1 | |
| Medical Management Alone | 107 | 82.9 | |
| Treatment with Corticosteroidsa Alone | 84 | 65.1 | |
| Treatment with Corticosteroids and One Additional Immunosuppressive Agentb | 16 | 12.4 | |
| Treatment with Corticosteroids and Multiple Additional Immunosuppressive Agents | 10 | 7.8 | |
| Treatment Outcomes ( | n | % | |
| Full Remission with Medical Treatment | 89 | 90.0 | |
| Full Remission with Corticosteroids Alone | 67 | 67.7 | |
| Intolerance, Relapse with Taper, or Treatment Failure with Corticosteroids as First Line | 32 | 32.3 | |
| Full Remission with Addition of Single Immunosuppressive Agent to Corticosteroids | 14 | 14.1 | |
| Full Remission with Addition of Multiple Immunosuppressive Agents to Corticosteroids | 8 | 8.1 | |
| Remission Not Achieved | 9 | 9.1 | |
aCorticosteroids included: prednisolone, methylprednisone and triamcinolone injections
bAdditional immunosuppressive agents included: rituximab, methotrexate, azathioprine, mycophenolate mofetil, tamoxifen, 6-mercaptopurine, chlorambucil, cyclosporine and cyclopohosphamide